Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 294

recruiting
3 977
countries
28
conditions
2 105

3 664 trials match your criteria

Study on Volixibat for Treating Itching in Patients with Primary Biliary Cholangitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Volixibat

Study of Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Hodgkin's disease

Not recruiting

Study Comparing MK-4280A (Favezelimab and Pembrolizumab) with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Colitis ulcerative

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Ustekinumab

Study on the Safety and Effectiveness of SerpinPC for Patients with Hemophilia B with Inhibitors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Study of Pembrolizumab, Paclitaxel, and Bevacizumab for Patients with Platinum-Resistant Recurrent Ovarian Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Neoplasm

Not recruiting

Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin

Study of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel

Study to Determine Safe Doses of Selexipag for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Selexipag

Study on Ampreloxetine and Midodrine Hydrochloride for Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ampreloxetine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.